Covid Positive	Covid negative		Percent with feature *	Percent COVID positive	Hazards ratio	95% CI	P	Comments
ALL PATIENTS
Sarcoidosis	9	502	511		1.76%
Sarc patients
Male	3	205	208	40.70%	1.44%	0.87	0.203-3.628	>0.10
Female	5	293	298	58.32%	1.68%				5 no sex identified
Black	0	6	6	1.17%	0.00%				less than 10 blacks
White	9	483	492	96.28%	1.83%				13 no race indicated
Roommate with COVID
yes	5	3	8	1.57%	62.50%	205.8	36.24-1169.14	<0.0001
no	4	494	498	97.46%	0.80%				5 no answer
Health care provider
Yes	2	45	47	9.20%	4.26%	2.89	0.583-14.324	>0.10
no	7	455	462	90.41%	1.52%				2 no answer
Current meds *
Prednisone	1	260	261	51.08%	0.38%	0.12	0.015-1.017	0.052
No prednisone	7	226	233	45.60%	3.00%				17 no answer
Prednisone>10 mg	1	83	84	16.44%	1.19%
Prednisone<10 mg	0	177	177	34.64%	0.00%	6.38	0.257-158.215	>0.10	only 1 COVID on predniso ne
anti-TNF	0	9	9	1.76%	0.00%	3.23	0.1697-61.655	>0.10
no anti-TNF	6	399	405	79.26%	1.48%				97 no answer
Cytotoxic	2	86	88	17.22%	2.27%	1.55	0.307-7.793	>0.10
No cytotoxic	6	399	405	79.26%	1.48%				18 no answer
Rituximab
No rituximab									No answers on ritux
Underlying
COPD	2	48	50	9.78%	4.00%	2.68	0.542-13.289	>0.10
	7	451	458	89.63%	1.53%				3 no answer
Diabetes	0	32	32	6.26%	0.00%	0.76	0.043-13.328	>0.10
	9	468	477	93.35%	1.89%				2 no answer
Heart disease									not answered
Hypertension	4	126	130	25.44%	3.08%	2.37	0.628-8.980	>0.10
	5	374	379	74.17%	1.32%				2 did not nswer
Organ involved*									If no response , assume
Lung	9	459	468	91.59%	1.92%	1.67	0.096-29.299	>0.10	not involved
	0	40	40	7.83%	0.00%				3 did not answer
Cardiac sarc	2	33	35	6.85%	5.71%	4.03	0.806-20.198	0.0896
	7	466	473	92.56%	1.48%				3 did nto answer
Neuro sarc	0	23	23	4.50%	0.00%	1.07	0.060-18.895	>0.10
	9	476	485	94.91%	1.86%				3 did not answer
Sarcoid age
Covid Positive							55.0 ± 8.63 years	>0.10
Covid negative							51.8 ± 9.74 years
COVID outcome	Home	Hospital	ICU	Vent
Sarc	7	2	1	0

*Percent positive of 511 patients who participated in study.